

# Continuous glucose monitoring amongst pregnant women with early-onset type 2 diabetes

<b>Submission date</b> 19/10/2023	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/10/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 01/11/2023	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Previous studies have shown that Continuous Glucose Monitoring (CGM) improves maternal glucose, reduces neonatal admissions and is clinically and cost-effective in type 1 diabetes (T1D) pregnancy, and as a result CGM is now standard care in T1D pregnancy. However, there are no well-designed adequately powered trials to compare CGM and standard care monitoring of blood glucose in type 2 diabetes (T2D) pregnancy.

The purpose of this study is to examine whether using CGM improves glucose levels in pregnant women with T2D and whether it leads to better outcomes for the baby. We will also look at its impact on maternal wellbeing, diabetes treatment satisfaction, and cost effectiveness.

### Who can participate?

We are aiming to recruit 422 pregnant women aged 16 years and above with T2D.

### What does the study involve?

Eligible participants will be approached early in pregnancy and if consent is given they will be enrolled. All participants will wear a masked sensor for 7-14 days to collect baseline CGM data. Participants will then be randomly allocated to receive either study CGM or the current standard of care (fingerprick blood glucose monitoring, or continuous glucose monitoring) for the rest of pregnancy.

Study visits are aligned with routine antenatal visits every 4 weeks. A blood sample for metabolic phenotyping will be obtained at the recruitment visit. The participant will be asked to complete questionnaires at the recruitment visit and then again at around 32 weeks' gestation. Blood samples for HbA1c will be taken at baseline, 28-week, 32-week, and 36-week visits. Participants in the control arm will wear a masked sensor for 14 days at 20, 28, 32 and 36 weeks' gestation. Following delivery we will collect information on birth and infant. 20-25 participants will also be interviewed at baseline and around 32-36 weeks' gestation to examine, among other things, barriers and facilitators for CGM use in this population.

What are the possible benefits and risks of participating?

None

Where is the study run from?

University of East Anglia (UK)

When is the study starting and how long is it expected to run for?

May 2023 to April 2027

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

Corinne Collett, C.Collett@uea.ac.uk

protect.trial@uea.ac.uk

## Contact information

### Type(s)

Scientific, Principal Investigator

### Contact name

Prof Helen R Murphy

### ORCID ID

<http://orcid.org/0000-0002-5489-0614>

### Contact details

Norwich Medical School, Floor 2, Bob Champion Research and Education Building, University of East Anglia, Norwich Research Park

Norwich

United Kingdom

NR4 7UQ

+44 (0)1603 591657

Helen.Murphy@uea.ac.uk

### Type(s)

Scientific, Principal Investigator

### Contact name

Prof Eleanor Scott

### ORCID ID

<http://orcid.org/0000-0001-5395-8261>

### Contact details

LICAMM, LIGHT Laboratories, Clarendon Way, University of Leeds

Leeds

United Kingdom

LS2 9JT  
+44 (0)113 343 7762  
E.M.Scott@leeds.ac.uk

**Type(s)**

Public

**Contact name**

Ms Corinne Collett

**ORCID ID**

<http://orcid.org/0000-0002-5510-1488>

**Contact details**

Norwich Clinical Trials Unit  
Norwich Medical School  
University of East Anglia  
Norwich  
United Kingdom  
NR4 7TJ

-

C.Collett@uea.ac.uk

**Type(s)**

Public

**Contact name**

Dr Study Team

**Contact details**

Norwich Clinical Trials Unit  
Norwich Medical School  
University of East Anglia  
Norwich  
United Kingdom  
NR4 7TJ

-

protect.trial@uea.ac.uk

## **Additional identifiers**

**EudraCT/CTIS number**

Nil known

**IRAS number**

331906

**ClinicalTrials.gov number**

Nil known

## Secondary identifying numbers

CPMS 58352, NIHR150958, IRAS 331906

# Study information

## Scientific Title

Pregnancy Outcomes using continuous glucose monitoring TEchnology in pregnant women with early-onset Type 2 diabetes: A multicentre randomised controlled trial of the clinical and cost-effectiveness of using continuous glucose monitoring (CGM) in pregnant women with early-onset type 2 diabetes

## Acronym

PROTECT

## Study objectives

In pregnant women with early-onset type 2 diabetes, the use of real-time CGM is more effective than standard clinical care (finger-prick self-monitoring blood glucose testing, continuous glucose monitoring) for improving the percentage of time spent in the pregnancy target glucose range of 3.5-7.8 mmol/L and reducing clinically relevant neonatal morbidity (neonatal care admission) or perinatal death.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

Approved 19/09/2023, South Central - Berkshire B Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048276; berkshireb.rec@hra.nhs.uk), ref: 23/SC/0315

## Study design

Interventional randomized controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Home, Hospital

## Study type(s)

Other

## Participant information sheet

## Health condition(s) or problem(s) studied

Early-onset type 2 diabetes in pregnancy

## Interventions

Recruitment visit: When women have expressed their wish to participate, they will be invited for the recruitment visit, when the following activities will be performed by the research team:

- Checking inclusion and exclusion criteria
- Written informed consent
- Baseline socio-demographic data collection
- Relevant medical / obstetric history and present medical (diabetes, comorbidity, medication, and obstetric) information
- Body weight and height, calculation of BMI
- Early pregnancy HbA1c recorded (or performed if not previously done in this pregnancy)
- Blood sample taken for metabolic phenotyping (C-peptide, autoantibodies, genetic risk score)
- Baseline questionnaire pack provided for participants to complete at home (either paper or electronically via link)
- Masked Freestyle Libre 3 sensor insertion (ideally 2 weeks prior to randomisation)

Women will have a small glucose sensor inserted under the skin by the clinical research team and will be instructed to wear it at home for up to 14 days. They will not be able to see the glucose information from this sensor.

Randomisation visit:

Ideally the sensor will be in place for 14 days, however if necessary to meet timelines, at least 3-4 days of CGM data should be available prior to randomisation (prior to 16 weeks' gestation). At the randomisation visit, the following will be performed:

- Masked CGM sensor upload & review (to confirm adequate baseline data available). Those randomised to the intervention arm will have access to the data from the masked sensor period following randomisation.
- Collection / confirmation of completed baseline questionnaires
- Record average total daily dose (TDD) of insulin during the previous 3 days
- Randomisation via study website
- Participant training

Participants in the CGM group will be shown how to apply the sensor, how to understand and use the CGM apps, how to interpret the data to guide decisions on eating and activity, recommended targets, and metformin / insulin dose adjustment.

Participants in the control arm will receive fingerstick self-monitoring blood glucose or continuous glucose monitoring training per local standard of care, along with advice on recommended targets, managing their diabetes in pregnancy, and metformin/insulin dose adjustment if relevant.

Participants will use their allocated glucose monitoring method throughout pregnancy, until after delivery.

Subsequent Study Visits

Follow up visits will be every 4 weeks at ~16/40, 20/40, 24/40, 28/40, 32/40, 36/40. It is expected that study visits will align with routine NHS antenatal clinic visits however virtual study visits will be offered if appropriate.

At these visits the following data will be recorded on the study database:

- Weight
- Blood pressure
- Glucose monitoring method(s), frequency of glucose testing
- Insulin delivery method(s), dose and type
- Adverse events of special interest

In addition, the following will be performed at key visits:

- Masked CGM for control group participants (14 days data collection) at 20, 28, 32, and 36 weeks' gestation

- Blood collection for HbA1c at 28, 32, and 36 weeks' gestation
- Follow-up questionnaires at 32 weeks' gestation

#### Delivery visit

The following obstetric and neonatal outcomes will be collected:

- Mode of delivery (vaginal, instrumental, elective/emergency caesarean section)
- Gestational age at delivery and indication for any preterm delivery <37 weeks
- Infant(s) birth weight
- Adverse events (pregnancy loss <24 weeks, stillbirth, neonatal death)

#### Neonatal follow up

Neonatal assessment is at hospital discharge (or 28 days if admission prolonged). The following data will be collected:

- Neonatal morbidity (treatment for neonatal hypoglycaemia, neonatal jaundice, respiratory distress)
- Neonatal care admission (duration of stay at each level of care)
- Infant feeding at hospital discharge
- Neonatal readmission in first 7 days after birth

#### Questionnaires

Participants will be asked to complete questionnaires at home, electronically or on paper, at baseline and again at 32 weeks:

- T2D Distress Scale (DDS)
- Glucose Monitoring Satisfaction Survey (GMSS)
- Patient Health Questionnaire 9-item depression scale (PHQ-9)
- Generalized Anxiety Disorder 7-item scale (GAD-7)
- EQ-5D

#### Optional qualitative interviews

20-25 participants will be purposively selected by socio-demographic factors to take part in the semi-structured interviews, in early pregnancy (after randomisation) and again at around 32-36 weeks' gestation. Interviews will take place remotely or in person.

#### Intervention Type

Device

#### Pharmaceutical study type(s)

Not Applicable

#### Phase

Not Applicable

#### Drug/device/biological/vaccine name(s)

Continuous glucose monitoring

#### Primary outcome measure

1. Percentage time spent with maternal glucose levels within target range as recorded by CGM Time-In-Range (TIR 3.5-7.8mmol/l) from 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
2. Neonatal unit admission or death (stillbirth/neonatal death) From randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)

## **Secondary outcome measures**

1. HbA1c & CGM mean glucose, GMI, frequency & duration of glycaemic excursions [%Time-Above-Range ( $\geq 6.7$  &  $\geq 7.8$  mmol/L), %Time-Below-Range ( $\leq 3.5$  &  $\leq 3.0$  mmol/L)], glycaemic variability (glucose SD, CV)] From 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
2. Hypertensive disorders from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
3. Gestational weight gain from baseline (early pregnancy) to last visit prior to delivery
4. Diabetes treatment (metformin & insulin use) From 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
5. Hospital admissions & duration of stay from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
6. Severe hypoglycaemia, hyperosmolar hyperglycaemic state, and diabetic ketoacidosis episodes from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
7. Gestational age at birth
8. Birth weight for gestational age (SDS) (GROW customised birth weight, LGA birth weight >90th centile or SGA <10th centile) at Birth
9. Mode of delivery at delivery
10. Neonatal unit admission >24hrs (duration of stay, highest level care) at Discharge after delivery
11. Adverse events (pregnancy loss <24 weeks, congenital anomaly (any), stillbirth, neonatal death) at Delivery
12. Birth injury (spinal cord injury, clavicular, skull or bone fracture, shoulder dystocia, nerve palsy, subdural or intracerebral haemorrhage, hypoxic ischaemic encephalopathy) at Birth
13. Neonatal morbidity (treatment for neonatal hypoglycaemia, respiratory distress requiring treatment, neonatal jaundice requiring treatment) at Discharge after delivery
14. Feeding at hospital discharge (exclusive breast-feeding / partial breast-feeding / exclusive formula feeding) at Discharge after delivery
15. Diabetes distress, anxiety & depression and treatment satisfaction using short questionnaires at Baseline & 32 weeks' gestation
16. Qualitative study to explore the acceptability, barriers, and facilitators for CGM use in T2D pregnancy at Baseline & 32-36 weeks' gestation
17. Incremental cost per quality-adjusted life year (QALY) at Randomisation to discharge after delivery

## **Overall study start date**

01/05/2023

## **Completion date**

30/04/2027

## **Eligibility**

### **Key inclusion criteria**

1. Type 2 diabetes (T2D)
2. 16 years of age or over
3. Confirmed pregnancy  $\leq 14$  weeks' gestation

4. HbA1c of  $\geq 43$  mmol/mol (6.1%) in pregnancy ( $\leq 14$  weeks' gestation)
5. Willingness to use the study devices throughout the trial
6. Able to provide informed consent

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

16 Years

**Sex**

Female

**Target number of participants**

Planned Sample Size: 422; UK Sample Size: 422

**Key exclusion criteria**

1. Non-type 2 diabetes
2. Chronic kidney disease (CKD) grade 4 or 5 (GFR  $< 30$ ml/min)
3. Severe visual impairment

**Date of first enrolment**

01/01/2024

**Date of final enrolment**

28/02/2026

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane

Colney

Norwich

United Kingdom

NR4 7UY

**Study participating centre**



**Leeds Teaching Hospitals NHS Trust**

St. James's University Hospital  
Beckett Street  
Leeds  
United Kingdom  
LS9 7TF

**Study participating centre****University College London Hospitals NHS Foundation Trust**

250 Euston Road  
London  
United Kingdom  
NW1 2PG

**Study participating centre****Calderdale and Huddersfield NHS Foundation Trust**

Trust Headquarters  
Acre Street  
Lindley  
Huddersfield  
United Kingdom  
HD3 3EA

**Study participating centre****Birmingham Women's and Children's NHS Foundation Trust**

Steelhouse Lane  
Birmingham  
United Kingdom  
B4 6NH

**Study participating centre****Guy's and St Thomas' NHS Foundation Trust**

St Thomas' Hospital  
Westminster Bridge Road,  
London  
United Kingdom  
SE1 7EH

**Study participating centre****University Hospitals of Leicester NHS Trust**

Leicester Royal Infirmary

Infirmery Square  
Leicester  
United Kingdom  
LE1 5WW

**Study participating centre**  
**West Hertfordshire Teaching Hospitals NHS Trust**  
Trust Offices  
Watford General Hospital  
Vicarage Road  
Watford  
United Kingdom  
WD18 0HB

**Study participating centre**  
**Imperial College Healthcare NHS Trust**  
The Bays  
St Marys Hospital  
South Wharf Road  
London  
United Kingdom  
W2 1BL

**Study participating centre**  
**Milton Keynes University Hospital NHS Foundation Trust**  
Standing Way  
Eaglestone  
Milton Keynes  
United Kingdom  
MK6 5LD

**Study participating centre**  
**Manchester University NHS Foundation Trust**  
Cobbett House  
Oxford Road  
Manchester  
United Kingdom  
M13 9WL

**Study participating centre**

**Bradford Teaching Hospitals NHS Foundation Trust**

Bradford Royal Infirmary  
Duckworth Lane  
Bradford  
United Kingdom  
BD9 6RJ

**Study participating centre**

**Sheffield Teaching Hospitals NHS Foundation Trust**

Northern General Hospital  
Herries Road  
Sheffield  
United Kingdom  
S5 7AU

**Study participating centre**

**Barts Health NHS Trust**

The Royal London Hospital  
80 Newark Street  
London  
United Kingdom  
E1 2ES

**Study participating centre**

**Liverpool Women's NHS Foundation Trust**

Liverpool Womens Hospital  
Crown Street  
Liverpool  
United Kingdom  
L8 7SS

**Study participating centre**

**Chelsea and Westminster Hospital NHS Foundation Trust**

Chelsea & Westminster Hospital  
369 Fulham Road  
London  
United Kingdom  
SW10 9NH

**Study participating centre**

**University Hospitals of Derby and Burton NHS Foundation Trust**

Royal Derby Hospital  
Uttoxeter Road  
Derby  
United Kingdom  
DE22 3NE

**Study participating centre****Croydon Health Services NHS Trust**

Croydon University Hospital  
530 London Road  
Thornton Heath  
United Kingdom  
CR7 7YE

**Study participating centre****Oxford University Hospitals NHS Foundation Trust**

John Radcliffe Hospital  
Headley Way  
Headington  
Oxford  
United Kingdom  
OX3 9DU

**Study participating centre****Newham University Hospital NHS Trust**

Newham General Hospital  
Glen Road  
London  
United Kingdom  
E13 8SL

**Study participating centre****West Middlesex University Hospital**

Twickenham Road  
Isleworth  
United Kingdom  
TW7 6AF

**Sponsor information**

**Organisation**

University of East Anglia

**Sponsor details**

Norwich Research Park  
Earlham Road  
Norwich  
England  
United Kingdom  
NR4 7TJ  
+44 1603 289863  
researchsponsor@uea.ac.uk

**Sponsor type**

University/education

**Website**

<https://www.uea.ac.uk/>

**ROR**

<https://ror.org/026k5mg93>

**Funder(s)****Funder type**

Government

**Funder Name**

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)

**Results and Publications****Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

**Intention to publish date**

31/01/2028

**Individual participant data (IPD) sharing plan**

The current data sharing plans for this study are unknown and will be available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date